Julian Rees
Co-Founder & Chief Executive Officer HOPO Therapeutics
Seminars
Thursday 23rd July 2026
Overcoming Resistance and Tumor Heterogeneity in Small-Cell Lung Cancer by Targeting DLL3 to Unlock New Therapeutic Opportunities
12:00 pm
- Exploring novel treatment strategies for a historically difficult-to-treat cancer
- Leveraging multiple therapeutic modalities, from ADCs to TRPs, to target DLL3
- Unlocking potential for better patient outcomes despite tumor heterogeneity and therapy resistance
